Myeloid differentiation (MyD) primary response and growth arrest DNA damage (Gadd) genes comprise a set of overlapping genes, including known (IRF-1, EGR-1, Jun) and novel (MyD88, Gadd45␣, MyD118/Gadd45␤, GADD45␥, MyD116/ Gadd34) genes, that have been cloned by virtue of being coordinately induced upon the onset of terminal myeloid differentiation and following exposure of cells to stress stimuli. In recent years it has become evident that MyD/Gadd play a role in blood cell development, where they function as positive regulators of terminal differentiation, lineage-specific blood cell development and control of blood cell homeostasis, including growth inhibition and apoptosis. MyD/Gadd are also involved in inflammatory responses to invading micro-organisms, and response to environmental stress and physiological stress, such as hypoxia, which results in ischemic tissue damage. An intricate network of interactions among MyD/GADD genes and gene products appears to control their diverse functions. Deregulated growth, increased cell survival, compromised differentiation and deficiencies in DNA repair are hallmarks of malignancy and its progression. Thus, the role MyD/Gadd play in negative growth control, including cell cycle arrest and apoptosis, and in DNA repair, make them attractive molecular targets for tumor suppression. The role MyD/Gadd play in innate immunity and host response to hypoxia also make these genes and gene products attractive molecular targets to treat immunity and inflammation disorders, such as septic shock and ischemic tissue damage.
cell lineages, including proliferation and terminal differentiation of cells along the myeloid lineage.
To better understand the molecular pathways that control terminal differentiation, myeloid differentiation primary response (MyD) genes, induced in the absence of de novo protein synthesis upon the onset of M1 leukemic myeloblasts for terminal differentiation by IL-6, have been isolated in our laboratory ( Figure 1a ). [1] [2] [3] [4] [5] [6] [7] MyD genes were also found to be induced during terminal differentiation which is coupled to cell proliferation in normal bone-marrow derived myeloblasts ( Figure 1a ). [1] [2] [3] [4] [5] [6] [7] Shortly after their isolation, a remarkable overlap was observed between two of the novel MyD genes and the Gadd genes, a group of growth arrest and DNA damage-induced genes induced by genotoxic stress (including alkylating agents and irradiation). [8] [9] [10] MyD116 was found to be the murine homologue of the hamster Gadd34 gene, 9 whereas MyD118 (Gadd45␤) and Gadd45 (Gadd45␣) were found to represent two separate, but closely related genes. 8 Recently, the full length sequences of murine and human CR6 (cytokine response gene 6) (Gadd45␥), a third member in the MyD118/GADD45 family, originally identified as an immediate-early response gene in T cells, 11 have been determined. [12] [13] [14] [15] Since terminal differentiation is associated with growth arrest and apoptosis, it is not surprising, that many of the genes identified as MyD genes, including both known genes (IRF-1, Jun, Egr-1) [2] [3] [4] and novel ones (MyD88, MyD116/Gadd34, MyD118(Gadd45␤)), [5] [6] [7] turned out to play a role in negative growth control, including growth suppression and apoptosis, induced by a variety of stress stimuli (Table 1) in many cell types. In recent years it also became evident that MyD/Gadd play prominent roles in host immunity and inflammation, consistent with their role as myeloid differentiation primary response genes (Table 2) . This review will examine the interrelated roles and molecular targets of known ((IRF-1, (AP-1) Jun/Fos, EGR-1)) and novel MyD/Gadd (MyD116, Gadd45␣, MyD118/Gadd45␤, CR6/Gadd45␥) in terminal differentiation of hematopoietic cells, and host stress responses including cell cycle arrest, DNA repair, apoptosis, immunity and inflammation ( Figure 2 and Table 2 ). The potential role of MyD/Gadd as therapeutic targets for the treatment of cancer and immune/inflammation disorders will be addressed as well.
MyD32: interferon regulatory factor 1 (IRF-1) in hematopoiesis, immunity and negative growth control
MyD32, is a MyD gene that was observed to be highly expressed in normal myeloblast-enriched bone marrow cells, and later on has been identified as the gene which encodes for interferon regulatory factor-1 (IRF-1), 2 Refs 195, 196 See text for details.
a transcriptional
activator of the interferon-␤ (IFN␤) gene. [16] [17] [18] IRF-1 is rapidly induced in the absence of de novo protein synthesis in M1 myeloblastic leukemia cells induced for terminal differentiation by IL6 or leukemia inhibitory factor (LIF). IRF-1 induction in M1 cells appears to be essential for expression of interferon-␤ (IFN␤) that is induced at later times ( Figure 1a ). M1 growth suppression associated with terminal differentiation was partially abrogated by IRF-1 antisense oligomers or IFN␤ antiserum. 2 Taken together, these findings reveal a regulatory cascade, where induction of terminal myeloid differentiation by IL6 or LIF triggers immediate-early activation of IRF-1 inducing IFN␤ expression, which in turn plays an autocrine role in growth inhibition associated with the terminal differentiation program (Figure 1a ). M1 myeloblasts, like normal hematopoietic progenitors, 19 undergo apoptosis at the end of the terminal differentiation program (Figure 1a ). Whether IRF-1 plays a role in apoptosis associated with terminal differentiation remains to be established. Nevertheless, consistent with a role for IRF-1 in hematopoiesis, targeted disruption of IRF-1 revealed a critical role for IRF-1 in T cell development resulting in a profound reduction in TCR␣␤
+ T cells. Moreover, mice deficient in IRF-2, an antagonistic repressor of IRF-1, exhibit bone marrow suppression of hematopoiesis and B lymphopoiesis, which likely is due to dysregulated expression of IRF-1 in hematopoietic cells. 
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Figure 1
Myeloid differentiation (MyD) and growth arrest DNA-damage primary response genes in stress responses and terminal hematopoietic differentiation.
Figure 2
MyD/Gadd molecular targets.
vator of the IFN␣␤ genes in virus-infected cells, which is a central event in innate immunity (Refs 21, 22 and Refs therein). In addition to antiviral responses, IRF-1 has been identified as a key regulator of innate and adaptive host immune and inflammatory responses to bacterial infections, mediated by IFN␥ and other inflammatory cytokines. 21 Major sources for IFN␥ are natural killer (NK) cells and T helper type 1 (TH-1) CD4
+ T cells (Refs 21and 23, and Refs therein). In TH1 cells, two distinct receptor-mediated pathways induce IFN␥ production. 23 T cell receptor (TCR)-dependent IFN␥ proLeukemia duction in response to IL-12 is antigen-specific and is considered to be part of the acquired immune response. On the other hand, differentiated TH1 cells, that express both IL-12 and IL-18 receptors produce IFN␥ directly in response to these cytokines. This second pathway, which enables TH1 cells to participate in non-antigen-specific responses, is considered as part of the innate pathway of T cell activation. It was shown that activation of the gene encoding for the p40 subunit of IL-12 is completely dependent on IRF-1 ( Figure 2) . 24, 25 Evidence has been obtained that IRF-1 also regulates IL-18 production and 
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Leukemia activity by modulating expression of caspase-1 and the IL-18 binding protein (Figure 2 ). In addition, IRF-1 participates in the induction of IFN␥ by IL-18. 26 These findings provide an explanation for the role IRF-1 plays in innate and adaptive immune responses to bacterial infections. Importantly, these observations also establish a functional link between IRF-1, MyD88, MyD118/Gadd45␤ and CR6/Gadd45␥ (Figure 2 and see below) .
IRF-1 is expressed in many cell types where it plays a role in negative growth control, including in cell cycle arrest and apoptosis. 21 Evidence for the growth suppressive function of IRF-1 was provided by the fact that mouse embryonic fibroblasts (MEFs) which lack IRF-1 are deficient in their ability to undergo DNA damage-induced cell cycle arrest. 27 Transcriptional activation of the cyclin-dependent kinase inhibitor (CDKI) p21 in these cells by irradiation was observed to be dependent both on p53 and IRF-1, providing an explanation for the compromised DNA damage-induced cell-cycle arrest of IRF−/−MEFs. That these two growth suppressive genes converge in the regulation of cell cycle arrest via activation of common target genes is also demonstrated by the fact that induction of ectopically expressed IRF-1 increased expression of p21 and inhibited cell growth. 28 Interestingly, the promoter regions of IRF-1 and p53 contain a common cis-acting sequence element, termed IRF-1 p53 common sequence (IPCS). Transcriptional activation of IPCS is strictly dependent on the binding of an IPCS-binding factor (IPCS-BF), indicating that expression of these two growth suppressive genes is also under common regulation. 29 Taken together, what has been discussed above suggests that IRF-1 functions as a tumor suppressor gene whose loss of function contributes to oncogenesis. Consistent with this notion, Harada et al 30 have shown that balanced expression of IRF-1 and IRF-2 is critical for normal cell growth. Overexpression of IRF-2 in NIH 3T3 cells resulted in transformation, whereas simultaneous overexpression of IRF-1 and IRF-2 reverted the transformed phenotype. Loss of IRF-1 dramatically increased the incidence of tumor development in mice which are transgenic for oncogenic ras or are deficient in p53. 31 The tumor suppresser function of IRF-1 is further highlighted by the involvement of IRF-1 in human cancer. This was first suggested by the work of Willman et al, 32 who demonstrated that the IRF-1 gene maps to human chromosome 5q31.1, a region which is frequently deleted in acute myeloid leukemia (AML) and preleukemic myelodysplasia (MDS). Loss of IRF-1 function in AML/MDS patients also is due to exonskipping in the error-prone IRF-1 mRNA. 33, 34 Frequent loss of IRF-1 in esophageal and gastric cancers has also been observed. [35] [36] [37] Kroger et al 38 have shown that IRF-1 suppresses hepatocellular carcinoma (HCC), which is a highly malignant tumor with a poor prognosis and few therapeutic options. IRF-1-mediated suppression of HCC was found to be due to a direct antitumor growth effect, as well as due to enhanced immune cell recognition of the tumor, suggesting that IRF-1 may be a promising candidate for gene therapy of HCC.
IRF-1 is also implicated in apoptotic cell death. IRF-1-deficient MEFs, unlike wild-type MEFS requiring co-operation of two oncogenes for transformation, 39 are readily transformed by ectopic expression of activated c-Ha-ras only. The transformed phenotype of ras-expressing IRF-1−/− MEFs could be suppressed by ectopic expression of IRF-1. Moreover, expression of the c-Ha-ras oncogene, when combined with a block to cell proliferation or treated by anticancer drugs or ionizing radiation, results in apoptosis of the wild-type, but not the IRF-1−/−, MEFs. 40 Taken together, these observations indicate that IRF-1 is a critical determinant of oncogene-induced apoptosis, where its loss increases susceptibly of cells for transformation. IRF-1 is also involved in DNA damage-induced apoptosis of mitogen-activated mature T lymphocytes, which is p53 independent. 41 Activation of capase 1 and 7 has been implicated in IRF-1-induced apoptosis. 42 Lee et al 43 have shown that IRF-1 and caspase-11 are the essential molecules in LPS/IFN␥-mediated microglial cell death, where IRF-1 is required for NO synthesis, and caspase-11 is necessary for NO-independent apoptotic pathway. The role of IRF-1 in immunityassociated apoptosis has been extended by Tendler et al 44 showing that IRF-1 plays a major role in anti-tumor immunity which is conveyed by activated macrophages. Hypoxia stimulates IFN-primed macrophages to express the inducible nitric oxide synthase (NOS2) and to synthesize nitric oxide (NO). The synergy between IFN and hypoxia was shown to be mediated by direct interaction of the hypoxia-inducible factor-1 (HIF-1) and IRF-1, both of which are required for the hypoxic transcription of NOS2. The interaction between HIF-1 and IRF-1 explains, at least partially, the mechanism by which macrophages infiltrating into tumors are activated to express NOS2 and to produce NO, which is a mediator of tumor apoptosis. Suk et al 45 have shown that IFN␥ and TNF␣ synergistically act to destroy ME-180 tumor cells either by apoptosis or necrosis, depending on caspase activation. STAT1/IRF-1 pathways, initiated by IFN␥, play a critical role in IFN␥/TNF␣ synergism presumably by inhibiting the cytoprotective effects of NF-kB. The same group of investigators has also demonstrated that a combination of IFN␥ and TNF␣ induces caspase-dependent apoptosis in insulinoma and pancreatic islet cells. IRF-1 was found to play a central role in IFN␥/TNF␣-induced cytotoxicity, since inhibition of IRF-1 induction by antisense oligonucleotides blocked IFN␥TNF␣-induced cytotoxicity, whereas overexpression of IRF-1 rendered insulinoma cells susceptible to TNF␣-induced cytotoxicity. 46 Furthermore, IRF-1 was observed to be involved in signaling via death receptors such as the Fas(CD95)/FasL apoptotic pathway (Figure 2) . 47 Deletion and mutagenesis of a putative IRF-1 binding site in the FasL promoter resulted in deficient expression of FasL, whereas forced expression of either IRF-1 or IRF-2 led to FasL promoter activation in T cells. 48 These findings suggest that the pro-apoptotic function of IRF-1, at least in part, is mediated via activation of the Fas/FasL pathway.
In conclusion, current knowledge indicates that IRF-1 has multiple interrelated biological functions. IRF-1, by regulating activation of IFNs, plays a role in host immune and inflammatory responses to various viral and bacterial pathogens. IRF-1, via its growth suppressive and pro-apoptotic functions, also plays a role in regulating cell homeostasis, including homeostasis of hematopoietic cells. Clearly, these biological functions, make IRF-1 an attractive therapeutic target for treatment of cancer and immunity/inflammation disorders, as further discussed below.
MyD21, MyD42, MyD63: Jun/Fos transcription factors in hematopoietic differentiation and as modulators of stress-induced apoptosis
MyD21, MyD42, and MyD63 were identified as MyD genes encoding for leucine zipper proteins that are rapidly and stably induced during differentiation of M1 myeloblastic leukemia cells, and myeloblast-enriched bone marrow cells. Shortly after their isolation cloning of c-jun, JunB and JunD has been reported, [49] [50] [51] [52] [53] and it became evident that MyD21,
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MyD42 and MyD63 encode for junB, c-Jun and JunD, respectively. 1, 3, 54 The fact that jun mRNAs are stably induced during hematopoietic differentiation suggests that Juns play key roles in the initiation, progression and maintenance of the myeloid differentiation program. C-jun, junB and junD are components of the AP-1 family of homo-and heterodimeric leucine ziper transcription factors, which also includes Fos and Fos related proteins (Ref. 55 and Refs therein). It has been established that Jun proteins homo-and heterodimerize with each other, whereas Fos proteins need Juns to form stable AP-1 complexes (Ref. 55 and Refs therein). Intriguingly, it was observed that though c-fos is stably induced during normal hematopoietic differentiation, it is not induced upon terminal myeloid differentiation of M1 myeloblastic leukemia cells. 56 Ectopic expression of Fos in M1 cells resulted in increased propensity of the cells to differentiate in culture, and tempered their leukemogenicity in nude mice. 56 Blocking Fos expression, using c-fos antisense oligomers, impaired terminal differentiation of normal, and M1 leukemic myeloblasts, implicating Jun/Fos as positive modulators of hematopoietic differentiation. The fact that M1 cells expressing physiological levels of Fos, comparable to those observed in differentiating bone marrow, could not be established 56 has raised the possibility that high levels of c-fos expression in hematopoietic progenitor cells may be antagonistic to cell growth and/or cell survival. Indeed, expression of a ␤-estradiol inducible FosER chimera in M1 myeloblasts cultured in the absence of a differentiation inducer resulted in apoptotic cells death (Ref. 55 and unpublished data), suggesting that under certain conditions of physiological and environmental stress Fos plays a role in monitoring hematopoietic progenitor cell survival (see below). The molecular nature of Jun/Fos transcription complexes that promote myeloid differentiation and/or programmed cell death remains to be established. In recent years ample evidence has accumulated that Jun/Fos transcription complexes, indeed play a role in the development of hematopoietic precursor cells along most, if not all of the hematopoietic cell lineages, including the monocyte/macrophage, granulocyte, megakaryocyte, mastocyte, erythroid and osteoclast lineages (reviewed in Refs 55 and 57). Most recently it was shown that transgenic mice which lack JunB expression in the myeloid lineage develop a transplantable myeloproliferative disease eventually progressing to blast crisis, resembling human chronic myeloid leukemia. 58 This indicates that JunB is a key transcriptional regulator of myelopoiesis and a potential tumor suppressor gene. It is possible, therefore, that JunB/Fos heterodimeric complexes promote differentiation. However, since cfos-deficient mice do not display the phenotype observed in junB null mice, it is clear that other AP-1 homo-and/or heterodimeric transcription complexes can compensate for the lack of Fos function.
Smeyne et al 59, 60 have been instrumental in suggesting that Jun/Fos play a role in apoptosis during early development and postnatally, upon terminal differentiation of many cell types. 59 High constitutive expression of fos is evident in sites of naturally occurring cell death. 60 The use of fos-and c-jundeficient mice, has shown that apoptosis can proceed normally during embryonic development of certain tissues and in some adult organs, such as the thymus and ovary, in the absence of Fos or c-Jun. 61 This may reflect functional redundancy of AP-1 complexes in promoting apoptosis in different cell types. A pro-apoptotic function for Fos was also observed in cell death induced by withdrawal of growth/survival factors. As mentioned above, activation of Fos in M1 myeloid progenitor cells in the absence of a differentiation inducer Leukemia resulted in loss of viability due to apoptotic cell death (Ref. 55 and unpublished) . Using PC12 pheochromocytoma cells and cultured neuronal cells has shown that inhibition of Fos or c-Jun activities, with dominant negative mutants that lack the c-Jun N-terminal activation domain or by neutralizing antibodies, protects the cells from apoptosis induced by withdrawal of nerve growth factor (NGF) or chronic depolarization. [62] [63] [64] [65] Ectopic expression of Fos or c-Jun was also observed to induce apoptosis in sympathetic neurons, in mouse fibroblasts, Syrian hamster embryo (SHE) cells and in human colorectal carcinoma (RKO) cells. 63, 66, 67 Evidence has been obtained that Jun/Fos complexes also modulate apoptosis after exposure of cells to genotoxic stress. Exposure of mammalian cells to UV light results in a UV response, which includes induction of many genes. 68, 69 Notably, there is an increase in the JNK/SAPK group of MAP kinases which results in increased AP-1 activity. 70, 71 Dominant negative cJun reduced apoptosis in human monoblastic leukemia cells after exposure to various DNA-damaging agents. 72 Both cjun−/− fibroblasts and Jnk1−/−/Jnk2− fibroblasts, were found to resist apoptosis induced by UVC radiation. 73, 74 c-jun−/− fibroblasts are also resistant to apoptosis induced by alkylating agents. 75 In contrast, a protective role for AP-1 in apoptosis induced by short-wavelength UV light (UVC) has been reported comparing survival of mouse 3T3 fibroblasts that are null for c-fos expression to their wild-type counterparts. 76 It has been suggested that the pro-apoptotic function of AP-1 is due to prolonged expression of c-Jun which overcomes the growth inhibitory effect of p53 by downregulating p21, which in turn promotes p53-mediated apoptosis. 73 Interestingly, the FasL gene was found to be a direct transcriptional target to Jun/Fos complexes (Figure 2) , 77, 78 suggesting that activation of the Fas/FasL death pathway also contributes to Jun/Fosmediated apoptosis.
In summary, Jun/Fos transcription complexes similar to IRF-1, play a role in hematopoietic differentiation and cell homeostasis, as well as in modulating programmed cell death in response to physiological and environmental stressors, including anti-cancer drugs. Thus, Jun/Fos transcription complexes are also attractive molecular targets for cancer treatment.
MyD19/HLM38: Egr-1-modulates hematopoietic lineagespecific differentiation and host stress responses
MyD19 and HLM38 were identified as myeloid differentiation primary response cDNAs, encoding for similar zinc finger proteins, that are rapidly induced upon activation of terminal macrophage differentiation in M1 myeloblastic leukemia cells and HL60 promyelocytic leukemia cells, respectively. Shortly after, it became evident that MyD19 and HLM38 encode for the mouse and human homologous of the then newly discovered zinc finger transcription factor EGR-1.
79-81 That Egr-1 was specifically induced upon induction of macrophages, but not granulocytes, differentiation has suggested that EGR-1 may play a lineage-specific role in hematopoietic development along the macrophage lineage. Indeed, using various myeloid differentiation inducible cell lines, we have shown that EGR-1 is a positive modulator of macrophage differentiation whose function varies, depending on the state of lineage commitment for differentiation and the hematopoietic cell type. In HL60 cells, EGR-1 was found to block granulocytic differentiation and restricted differentiation to the monocytic lineage. 82 EGR-1 also blocked G-CSF-induced differentiation of IL-3-dependent 32Dcl3 hematopoietic precursor cells, endowing the
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Leukemia cells with the ability to be induced by GM-CSF for terminal differentiation along the macrophage lineage. 83 Interestingly, EGR-1 was also found to mediate, in part, the ability of the homeobox gene Hox-B8 (Hox2.4) to endow 32Dcl3 cell with the potential to be induced by GM-CSF for terminal macrophage differentiation. 84 Furthermore, ectopic expression of EGR-1 in M1 myeloblastic leukemia cells activated the macrophage differentiation program, in the absence of the differentiation inducer IL-6. 85 Using high efficiency retroviral transduction, recently it was shown that ectopic expression of EGR-1 in normal hematopoietic progenitors stimulated their development along the macrophage lineage at the expense of development along the granulocyte and erythroid lineages, regardless of the cytokine(s) used. 86 
88,89 Recently, we have observed that depending on the cytokine(s) used and the hematopoietic cell type, either one, two or all four members of the Egr family are induced during myeloid differentiation (unpublished). Taken together, these observations strongly suggest that other member(s) of the Egr family are capable of compensating for the function of EGR-1 in macrophage development.
Recent work has demonstrated that Egr-1, like other MyD genes, also plays an important role in stress responses, including stress induced by genotoxic agents and ischemia. Both EGR-1 and TNF␣ are induced upon irradiation-induced apoptosis of prostate cancer cells that lack p53. 90 Inhibition of EGR-1 abrogated both TNF␣ induction and apoptosis. Induction of TNF␣ by ionizing radiation was shown to be mediated via an EGR-1-binding motif in the TNF␣ promoter, suggesting that, in the absence of p53, ionizing radiationinduced apoptosis is mediated by EGR-1 via TNF␣ trans-activation. 90 Transregulation of p53 by EGR-1 also has been implicated in EGR-1 mediated apoptosis. 92 In additon, like IRF-1 and Fos/Jun, evidence has been obtained that Egr-1 also participates in the regulation of expression of the pro-apoptotic FasL gene (Figure 2) . 91 Differential expression of Fas ligand in Th1 and Th2 cells is regulated by early growth response gene and NF-AT family members. Evidence has been obtained that EGR-1 is also an important player in the UV responses of mammalian cells. 93 Recently, EGR-1 has been identified as a master switch which in response to hypoxia coordinates up-regulation of divergent gene families, [94] [95] [96] [97] including inflammatory chemokines (ie IL-1), adhesion receptor, procoagulant and permeability-related genes, which underly the pathogenesis of ischemic tissue damage during reperfusion.
In summary Egr-1, like IRF-1 and Juns, is a MyD gene that plays a role in hematopoietic differentiation and host stress responses.
MyD88-a signal transducer in IL-1 and Toll receptor signaling: role in innate immunity, inflammation and apoptosis
MyD88 was originally characterized as a novel MyD gene in M1 myeloblastic leukemia cells induced for terminal macrophage differentiation by IL-6. 7 High levels of MyD88 were observed in myeloid enriched bone marrow cells, suggesting a role for this gene in myeloid cell function/development. Interestingly, MyD88 immediate-early induction, unlike other MyD genes, is largely regulated at the level of mRNA stability. 98 The role of MyD88 in terminal myeloid differentiation is still not fully understood. Given the role MyD88 plays in IL-1 and Toll-receptor signaling (see below), it is likely that induced expression of MyD88 in myeloid cells undergoing macrophage differentiation serves to prime the cells to respond to IL-1 and pathogen-associated motifs, respectively. Recent evidence has been obtained that in response to certain stimuli MyD88 also plays a role in dendritic cell maturation. 99 The MyD88 encoded protein (35 kDa) has a modular structure, consisting of an N-terminal death domain separated by a short linker from a C-terminal Toll domain (Figure 3 ). [100] [101] [102] [103] [104] [105] The N-terminal death domain is related to a motif that originally was defined as the region of similarity between the cytoplasmic tails of the FAS/Apol/CD95 and TNF receptors that is required for cytotoxic signaling by the so-called death receptors. 106, 107 The MyD88 C-terminal Toll domain, on the other hand, bears homology with the cytoplasmic signaling regions of the Drosophila melanogaster Toll receptor and the IL-1 receptor complex.
104,107-110 IL-1 is known as an important mediator of inflammation, which participates in the defense response to environmental challenges by generating fever, activating lymphocytes, and mobilizing leukocytes to sites of injury and infection. 111 IL-1 exerts its effects by inducing the transcription of genes which encode for chemokines, cytokines, acute-phase liver proteins, cell adhesion molecules, and enzymes involved in the production of pro-inflammatory substances. 111, 112 An important mediator of the IL-1 signaling cascade is NFB, 113, 114 which is rendered inactive in the cytoplasm of unstimulated cells by inhibitory proteins termed IKB (Figure 3 ). Upon exposure of cells to cytokines or stress stimuli, IKB proteins are phosphorylated on specific serine residues, and consequently are degraded, leading to nuclear translocation and activation of NFB. 115, 116 Stimulation of cells with IL-1 results in association of the IL-1 type I receptor (IL-1 Rl) with the receptor accessory protein (IL-1RAcP). [117] [118] [119] [120] Consequently, the IL-1 receptor-associated serine/threonine kinase (IRAK) is recruited to the receptor complex, where it is phosphorylated. 121 IRAK then dissociates from the receptor complex and interacts with TRAF6, which is required for IL-1-mediated activation of NFB 122 ( Figure 3) . Two other TRAF (TNF-receptor associated factor) proteins, TRAF2 and TRAF5, have been implicated in NFB activation by the superfamily of TNF receptors, [123] [124] [125] [126] [127] [128] indicating that IL-1 and TNF signaling converges at the level of TRAF molecules. The kinase cascade which is distal to TRAF, and is responsible for NFB activation, consists of a kinase complex that is composed of the TRAF interacting and NFB-inducing kinase (NIK), and two IKB kinases (IKK␣ and IKK␤) that phosphorylate IKB on specific serine residues (Figure 3 ).
129-135
The IL-1Rl and IL-1RAcP belong both to a conserved family of receptor-like molecules, including IL-1 Rrp, IL-1Rrp2, T1/ST2, rsc786/TIL, human Toll in mammals, 104, [136] [137] [138] [139] RPP5 in plants, 140 and 18 Wheeler and Toll in Drosophila. 108, 141 In Drosophila, the Toll pathway governs an ancient innate immune response. 142 In addition, this pathway controls dorsal-ventral polarization during early embryonic development. [143] [144] [145] Analogous to IL-1 signaling, activation of the cell surface receptor Toll by the extracellular ligand Spaetzle was shown to lead to the phosphorylation and degradation of the IKB-like molecule Cactus, resulting in release and translocation of the NFB-like transcription factor Dorsal to the
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Figure 3
MyD88 is a signal transducer in signaling by the IL-1, IL-18 and Toll receptors. MyD88 has a modular structure, consisting of an N-terminal death domain (DD) and C-terminal Toll domain (TD). MyD88 is an adapter that recruits the serine/threonine kinase IRAK to the IL-1, IL-18 and human Toll receptors. MyD88 is upstream of a regulatory cascade, which activates NF-KB and AP-1. MyD88 is the mammalian homologue of Drosophila Tube, and a functional equivalent of TRADD, a signal transducer in TNF signaling. TRADD interacts with RIP/TRAF2 to activate NF-KB, and with FADD to activate caspase 8 and apoptosis. MyD88 is capable of inducing apoptosis. Whether it functions like TRADD remains to be seen. nucleus (Figure 3) . [145] [146] [147] Dorsal activation signaled by Toll requires two intermediate signal transducers, Tube and Pelle. [145] [146] [147] Pelle is a serine/threonine kinase that is related by its sequence to IRAK, whereas Tube is an adapter molecule that links Pelle to the Toll receptor (Figure 3) . 148, 149 Tube and Pelle were observed to interact via their N-terminal death domains, a motif which is also present in many other signal transducing molecules, including IRAK. 100, 121, 148 In recent years it has become evident that MyD88 is the mammalian homologue of drosophila Tube, which recruits IRAK to the IL-1 receptor complex [150] [151] [152] thereby coupling a serine/threonine protein kinase to the IL-1 receptor complex, which ultimately results in activation of NFb and Jun/Fos transcription factor complexes (Figures 2 and 3) .
MyD88 also has been identified as an adapter for activation of NFB and AP-1, via the IRAK/TRAF6 cascade, in signaling by human Toll-like-receptors (TLRs) that play important roles in the innate immune response which is the first line of defense against infectious diseases (Figure 3) . 153, 154 For example, the inflammatory response to Gram-negative bacterial endotoxin (lipopolysaccharide (LPS)), that plays a key Leukemia role in septic shock syndrome, due to its profound effects on the innate immune system, is conveyed by TLR4 and is dependent on MyD88, as evident by the unresponsiveness of MyD88-deficient mice to endotoxin (Ref. 153 and Refs therein, and Ref. 155) (Figures 2 and 3) . Consistent with this notion, recently it has been reported that the Lps(d) mutation abolishes Toll receptor signaling by disrupting recruitment of MyD88. 156 Also, it has become evident that endotoxin tolerance, which is a common phenomenon in blood from sepsis patients, involves the inability of IRAK to associate with MyD88 in tolerant cells.
Gene targeting of MyD88 in mice has shown that mice lacking MyD88 have defects in T cell proliferation, as well as in the induction of acute phase liver proteins and cytokines in response to IL-1. 157 Interestingly, MyD88 null mice also exhibit defects in IL-18 signaling via the IL-1-related receptor-IL-Rrp. 157 Both the increase in IFN␥ production and natural killer cell activity in response to IL-18 are compromised in MyD88−/− mice. IL-18-induced activation of NFB and JNK was also impaired in MyD88−/−Th1-thymocytes. These observations indicate that MyD88 is a critical component in the IL-
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Leukemia 1 and IL-18 signaling cascades (Figures 2 and 3) . The fact that MyD88 gene disruption was not lethal, and did not affect early embryo development in mice, is consistent with the notion that other MyD88-like molecules, which play critical roles in Toll signaling in mammal development, might exist.
Identification of MyD88 as an adapter molecule that recruits IRAK to the IL-1 receptor complex extends the conservation found in the signaling pathways for IL-1 and TNF, two major cytokines that activate NFB (Figure 3 ). The TNFR1 complex was shown to recruit the death domain-containing molecule TRADD, 158 which mediates NFB activation and apoptosis. To activate NFB, TRADD interacts with the serine/threonine kinase RIP and TRAF2, that are linked to the NIK/IKK cascade, and trigger the phosphorylation and degradation of IKB. 125, 159 On the other hand, to induce cell death, TRADD interacts with FADD, which in turn triggers the apoptotic caspase cascade. 125, [160] [161] [162] Thus, in IL-1 signaling MyD88 is the functional equivalent of TRADD. Indeed, recently a role for MyD88 in programmed cell death has been established. Ectopic expression of MyD88 in human cervical carcinoma HeLa cell was observed to induce apoptosis. 163 Dominant negative MyD88 proteins inhibit interleukin-1beta/interferon-gammamediated induction of NFB-dependent nitrite production and apoptosis in pancreatic beta cells. 164 Evidence has been obtained that MyD88 also mediates apoptosis and activation of NFB upon activation of Toll receptor signaling by LPS. 165 In conclusion, MyD88 fulfills important roles in innate immunity, inflammation and its associated programmed cell death. Thus, molecular targeting of MyD88 in innate immunity disorders, notably in septic shock, is potentially of great therapeutic value. Furthermore, as elaborated below, the function of MyD88 is linked in several interesting ways to the function of other MyD genes, establishing a network of MyD/GADD functions that play key roles in cell homeostasis and host responses to environmental stress agents.
MyD116 viral homologs and role in apoptosis
MyD116 is the second novel MyD gene that was isolated in our laboratory. 6 Like other MyD genes it is rapidly induced by IL-6 in M1, and expressed in bone marrow cells. Following its isolation, it became evident that MyD116 is the murine homologue of Gadd34, that was isolated by virtue of its being activated in hamster cells by growth arrest and DNA-damage stimuli, including alkylating agents and irradiation. [8] [9] [10] An interesting feature of the MyD116/GADD34 proteins are the almost perfect 38/39 aa long repeats, each containing a PEST motif, implicated in rapid protein turnover. Each PEST motif contains three potential casein kinase II phosphorylation sites, the function of which is still unclear. Interestingly, MyD116 contains 4. repeats, whereas GADD34 harbors only 3. repeats. Cellular localization of the MyD116 protein has revealed that MyD116 is present both in the cytoplasm and in the nucleus of cells (unpublished). Using subtraction hybridization, a gene-termed PEG3, associated with transformation progression of virus-and oncogene-transformed rat embryo cells, has been cloned as a new member in the MyD116/Gadd34 family. 166 Interestingly, the conserved carboxy terminal domain of MyD116, shares striking homology to the corresponding domain in the ␥(1)34.5 gene of herpes simplex virus (HSV). 167 The HSV ␥(1)34.5 gene is essential for establishment of acute infection by HSV. Deletion mutants, of ␥(1)34.5 trigger a premature shutoff of all protein synthesis, thereby rendering the cell non-viable and preventing acute infection. 168 The ␥(1)34.5 domain necessary to preclude the total shutoff of protein synthesis was mapped to the carboxyl-terminal domain of the ␥(1)34.5 protein, which is highly homologous to the corresponding domains in MyD116 and GADD34. 168 It was shown that the carboxyl terminus of murine MyD116 can substitute for the corresponding domain of ␥(1)34.5 of HSV to preclude premature shutoff of protein synthesis in infected human cells. 169 The ␥(1)34.5 protein of HSV1 was found to complex with protein phosphatase-1␣. This interaction results in dephosphorylation of the ␣ subunit of the eukaryotic translation initiation factor 2, thereby precluding the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. The MyD116 homology domain has been implicated in this interaction. 170 Interestingly, the African swine fever virus virulence-associated gene, termed NL-S, also encodes for a protein with a carboxy terminal domain which is similar to the carboxy terminal domain of MyD116 and the HSV ␥(1)34.5 protein. [171] [172] [173] [174] Whether other viruses harbor similar genes that upon viral infection promote cell survival remains to be seen. Curiously, ectopic expression of mammalian MyD116 was found to suppress tumor cell growth. 10 On the other hand, blocking MyD116 expression by antisense oligos was observed to promote hematopoietic cell survival, suggesting that MyD116 plays a role in terminal differentiation-associated apoptosis (unpublished). Furthermore, cellular MyD116/ GADD34 has been reported to be induced by diverse apoptotic stimuli, in a way which suggests that activation of MyD116/GADD34 is a downstream event in apoptotic signaling pathways and may directly contribute to the apoptotic process. 175, 176 Thus, MyD116/GADD34 and ␥(1)34.5 appear to play opposing roles, where MyD116/GADD34 seems to induce apoptosis while ␥(1)34.5 inhibits apoptosis in virally infected cells. Recently MyD116/GADD34 has been implicated in dephosphorylation of eIF2alpha in a negative feedback loop that inhibits stress-induced gene expression, and that might promote recovery from translational inhibition in the unfolded protein response. 177 Interestingly, leukemic HRX fusion proteins were found to inhibit MyD116/GADD34-induced apoptosis via association with the MyD116/GADD34 protein, suggesting that MyD116/GADD34 function plays a role in suppression of leukemia. 178 Both the ␥(1)34.5 gene of HSV and MyD116/GADD34 were reported to interact via their conserved C-terminal domains, with proliferating cell nuclear antigen (PCNA), 179 an important player in DNA replication and DNA repair. The significance of this interaction remains to be determined. MyD116 was also found to interact with KIF3A, a kinesin superfamily protein, 180 with a new member of the Hsp40 family of heat shock proteins that is induced by a DNA-damaging agents, 181 with Translin, a protein that is known to bind to the DNA sequences detected in the DNA translocation 182 and with a zinc-finger transcription factor that binds to the p21 promoter. 183 The biological significance of these interactions remains to be established.
Thus, the function of MyD116/GADD34, like other MyD proteins, appears to relate to the regulation of programmed cell death.
MyD118(GADD45␤), Gadd45␣ and CR6(GADD45␥), a family of growth suppressive and apoptotic proteins which interact with cell cycle proteins
MyD118 is the third novel gene isolated in our laboratory. 5 Shortly after its isolation, it became evident that MyD118 is SPOTLIGHT related to the Gadd45 gene. The proteins encoded by these genes are 57% identical, indicating that MyD118 and Gadd45 represent two separate, but closely related genes. 10 Recently, the full-length sequences of murine and human CR6 cDNAs, respectively, have been determined. 12, 15 The MyD118/CR6/Gadd45 gene family (also termed Gadd45␤,Gadd45␥Gadd45␣
15 encodes for small (18 kDa), evolutionary conserved proteins that are highly homologous to each other (55-57% overall identity at the amino acid level), are highly acidic (pI, 4.0-4.2), and are primarily localized within the cell nucleus. 12, 15 The GADD45 family of proteins are rapidly induced by genotoxic agents, 10, 184, 185 as well as by terminal differentiation and apoptotic cytokines. 5, 10, 12, 186 In recent years evidence has emerged that these proteins play pivotal roles in negative growth control, either dependent or independent of p53, including the response of mammalian cells to genotoxic stress. 8, 9, 12, 187 Data accumulated so far, suggest that MyD118/ CR6/GADD45 serve similar, but not identical, functions along different apoptotic and growth inhibitory pathways. For example, we have observed that MyD118, but not Gadd45, is activated upon TGF-␤1 induced apoptosis. 188 On the other hand, Gadd45, but not MyD118 or CR6, was identified as a target for p53 function. [189] [190] [191] All three genes are induced with different expression kinetics during terminal hematopoietic differentiation, which is associated with growth arrest and apoptosis.
12 Distinct expression patterns for these genes were also observed in a variety of murine tissues. 12 Importantly, individual members of the GADD45 gene family are differentially induced by a variety of genetic and environmental stress agents; this suggests that each gene is induced by a distinct subset of environmental stresses. [12] [13] [14] [15] 192, 193 Short-term transfection assays have revealed that MyD118/CR6/ GADD45 synergize to suppress colony formation of several human tumor cell lines. 10, 12 To what extent the function of each of the MyD118/CR6/GADD45 proteins is unique or overlaps with the functions of the other proteins, remains to be determined.
GADD45 proteins have been implicated in cell cycle arrest, 11, 12, 194 DNA repair, 186, 195, 196 apoptosis, [13] [14] [15] [197] [198] [199] cell survival, 196, 200 and innate immunity. 222, 223 Microinjecting a GADD45␣ expression vector into primary human fibroblasts arrested the cells at the G2/M boundary of the cell cycle. 201 The ability of GADD45␣ to mediate G2/M arrest appears to depend on wild-type p53, since no arrest was observed in p53-null cells. Inhibiting endogenous Gadd45␣ expression by antisense Gadd45 expression, impaired G2/M checkpoint following exposure to UV radiation or MMS, but not following exposure to IR. These observations indicate the existence of multiple G2/M checkpoints, which are activated in response to different stress agents. Keeping in mind that Gadd45 is a transcriptional target for p53, these observations implicate Gadd45 in p53-mediated G2/M cell cycle arrest in response to certain genotoxic stress agents. 201 Recent data also indicate that MyD118/GADD45␤ and CR6/GADD45␥ play a role in G2/M cell cycle arrest. 202 Gadd45␣-deficient mice were observed to exhibit genomic instability and increased radiation carcinogenicity. 194 The genomic instability observed in Gadd45␣ null mice may reflect perturbations in one or more of the controls that regulate G2/M cell cycle progression.
Many observations are also consistent with a role for MyD118/CR6/GADD45 in programmed cell death. Blocking MyD118 expression via antisense transgenes in M1 myeloblastic leukemia cells impaired TGF␤-induced cell death, Leukemia implicating MyD118 as a positive modulator of TGF␤-induced apoptosis. 188 IPTG-inducible ectopic expression of MyD118 or CR6 accelerated TGF␤-induced apoptosis in M1 cells, 14 and enhanced apoptosis induced by genotoxic stress agents in both M1 and H1299 lung carcinoma cells. 13 Moreover, transient transfection of MyD118, Gadd45, or CR6 into H1299 cells resulted in apoptotic cell death. 15, 197, 199 Recently, GADD45␣ has also been implicated in p53-independent BRCA-1-mediated apoptosis of breast cancer cells. 198, 203 Furthermore, overexpression of GADD45␥ by microinjection of an expression vector into normal neurons cultured in the presence of NGF resulted in cell death. 204 Curiously, evidence has been obtained that under certain conditions, GADD45 proteins promote cell survival. Clonogenic survival assays with Gadd45a−/− MEFs 196 and RKO cells expressing antisense Gadd45␣ RNA 200 have shown that deficiency of GADD45 increases the sensitivity of cells to killing by UV irradiation or cisplatin. It appears, therefore, that the stress stimulus encountered, the cell type, its physiological state, its genetic makeup, and interaction with other proteins (see below) modulate GADD45 protein function to determine whether the outcome will be cell cycle arrest, DNA repair and cell survival or apoptotic cell death.
Evidence has accumulated that MyD118/CR6/Gadd45 display a complex array of physical interactions with each other (Ref. 205 and DL unpublished), as well as with other cellular proteins implicated in cell cycle regulation and the response of cells to extrinsic stress. All three GADD45 proteins interact with PCNA, 186, 195, 199 a nuclear protein that plays a central role in DNA repair and replication, and in at least one apoptotic pathway (Refs 206-208 and Refs therein). Recently, evidence has been obtained that GADD45␣ interaction with PCNA plays a role in nucleotide excision repair of DNA. 196 Recent evidence suggests that interaction of GADD45 proteins with PCNA in essence impedes their apoptotic function. 197, 199 Whether interaction of GADD45␤ and GADD45␥ with PCNA plays a role in DNA repair remains to be seen. Recently interaction of GADD45␣ with p33(ING1) has also been observed and suggested to play a role in NER. 209 Whether Gadd45␤ and/or GADD45␥ interact with ING1 is not known. Interaction of GADD45␣ with DNA and core histones has been reported recently, 210 and it has been suggested that this interaction is also linked to Gadd45␣ function in DNA repair.
Gadd45 proteins also interact with cdc2(Cdk1), resulting in inhibition of the kinase activity of the cdc2/CyclinB1 complex. [211] [212] [213] Since cdc2/cyclinB1 is known as a key regulator of the transition from G2 to the M phase of the cell cycle, 214, 215 interaction of Gadd45 proteins with cdc2 is implicated in GADD45-mediated activation of the G2/M checkpoint in response to genotoxic stress. 201, 202 All three GADD45 proteins were also found to interact 186, 199 with the universal cyclindependent kinase inhibitor p21, 216-218 a p53 target gene 219 implicated in G1/S 220 and G2/M 221 cell cycle arrest. The role of GADD45 interactions with p21 is still unclear. GADD45 proteins also interact with and activate the stress-responsive MTK1/MEKK4 kinase, which is an upstream activator of the p38/JNK kinase pathway implicated in environmental stressinduced apoptosis (Figure 2) . 15 However, the significance of GADD45 interactions with MEKK4 in activation of the stressresponsive JNK/p38 apoptotic pathways is still undetermined. 192, 193 Recently it has been suggested that GADD45␤ and GADD45␥ activation of JNK/p38 plays an essential role in cytokine-induced (innate) IFN␥ production by TH-1 thymocytes (Figure 3) . 222, 223 Finally GADD45 proteins are also capable of homo-and hetero-interactions among themselves (Ref.
SPOTLIGHT
Leukemia 205 and DL unpublished). The multitude of GADD45 interacting partners raises the interesting possibility that the nature/magnitude of stress encountered, and the extent of cellular/DNA damage may dictate association of GADD45 with particular partners, to determine the appropriate outcome, ie cell cycle arrest, DNA repair and cell survival or programmed cell death. Clearly, many data are still needed to better understand how the intricate network of GADD45 interactions with other cell cycle and stress response proteins mediates their diverse functions.
MyD/GADD as therapeutic targets for treatment of cancer and immune/inflammation disorders
What has been described above depicts an intricate network of interactions among MyD/GADD genes and gene products which appears to function in blood cell differentiation, cell homeostasis, and host stress responses ( Figure 1 , Table 2 ). It is evident that MyD/Gadd, each in its own way, play a role in blood cell development, where they function as positive regulators of the terminal differentiation program (jun/Fos), in lineage-specific cell development (EGR-1) and in the control of blood cell homeostasis including growth inhibition (IRF-1) and apoptosis (Jun/Fos, MyD118/GADD45␤, GADD45␣, GADD45␥, MyD116/Gadd34) ( Table 2 ). MyD/Gadd are also involved in inflammatory response to invading micro-organisms (IRF-1, MyD88, GADD45␤ GADD45␥), response to environmental stress (IRF-1, EGR1, MyD88, MyD116/ GADD34, MyD118/GADD45␤, GADD45␣ GADD45␥) and response to physiological stress, such as hypoxia, which results in ischemic tissue damage during reperfusion (EGR-1) ( Table 2) . Different downstream effectors involved in mediating these MyD/GADD functions are depicted in Figure  2 . These include: (1) IFN␤ and IFN␥ whose expression, in part, is controlled by IRF-1 MyD118/GADD45␤, and GADD45␥; (2) inflammatory cytokines such as FasL IL-1, IL-12 and IL-18 whose synthesis is modulated by IRF-1, EGR-1, and Jun/Fos; (3) intracellular stress mediators, including activation of MEKK4 an upstream regulator of the JNK/p38 stressactivated protein kinases, and activation of NFB by IRF-1 and MyD88. It is thus clear that MyD/Gadd in addition to the roles they play in blood cell differentiation, converge on common molecular pathways that mediate host responses to environmental stress including microbial, viral and physical/chemical stress agents.
Deregulated growth, increased cell survival, compromised differentiation and deficiencies in DNA repair are hallmarks of malignancy and its progression. [224] [225] [226] It is obvious, therefore, that MyD/Gadd, playing important roles in negative growth control, including cell cycle arrest and apoptosis (IRF-1, MyD118GADD45␤, Gadd45␣, GADD45␥, MyD116/ GADD34, Jun/Fos), and in DNA repair (MyD118/GADD45␤, GADD5␣), are attractive molecular targets for tumor suppression. The role MyD/Gadd play in innate immunity (IRF-1, MyD88, MyD118/GADD45␤, GADD45␥) and host response to hypoxia (EGR-1) make these genes and gene products also attractive molecular targets to treat immunity/ inflammation disorders, such as septic shock and ischemic tissue damage in response to hypoxia. Understanding how MyD/Gadd interact to regulate hematopoietic cell differentiation, cell homeostasis, and host stress responses should aid in the development of new drugs targeting MyD/GADD functions in cancer patients and in the treatment of immune and inflammation disorders.
